HemoShear Therapeutics, LLC, a privately held biotech company and CvilleBioHub member focused on discovering and developing drugs for metabolic disorders, recently appointed Kathleen M. Metters, PhD, to its board of directors. Metters has served as president and CEO of Lycera Corp. and held multiple leadership roles at Meck & Co., one being the Head of Worldwide Basic Research. Jim Powers, chairman and CEO of HemoShear, shared his excitement of bringing Dr. Metters on board, explaining “as HemoShear continues to develop novel treatments for metabolic disorders, Kathleen’s scientific and business acumen will bring great value across a range of activities as we advance our therapies toward the clinic, build our pipeline, and collaborate with pharma partners.”
A biopharma veteran for nearly three decades, Dr. Metters focused on creating a pipeline of immune modulator programs at her previous company, Lycera; from such research emerged an exclusive global collaboration with Celgene in 2015. Her career started as a research scientist at Merck & Co, where she resided for over 20 years and played a pivotal role in discovering SINGULAIR® for the treatment of asthma and allergic rhinitis. From that point, Metters rose to become a chair of the Worldwide Business Strategy team for the respiratory business, leader of Worldwide Basic Research and establish External Discovery and Preclinical Sciences. She has a rigorous academic background and authors over 70 publications, and is additionally listed on 29 patents.
Dr. Metters expressed her gratitude for joining HemoShear’s team as she stated “HemoShear has been both focused and comprehensive in bringing together several disciplines to create a robust drug discovery platform that has been incredibly successful in identifying new drug targets. I look forward to working with this talented team as the company advances its strategy to bring new treatments for rare metabolic diseases into the clinic”
For more information, view the original article by HemoShear Therapeutics here.
About HemoShear Therapeutics- HemoShear Therapeutics is a biotechnology company focused on discovering novel biological targets and developing drugs to treat children’s rare metabolic disorders. Their goal is to discover drugs that save the lives of children who are born with metabolic defects and are unable to sustain basic biochemical processes necessary for life. The company’s proprietary technology allows for recapitulation of diseases using tissue from livers of children born with genetic defects, interrogate the disrupted biochemical processes, explore drug intervention strategies, and select drug candidates that they believe have high probabilities of clinical success.